Form 4: Centessa Pharmaceuticals Executive Exercises Options and Sells Shares Under Pre-Arranged Plan

Centessa Pharmaceuticals plc's President of Orexin Program, Mario Alberto Accardi, executed a pre-planned transaction, exercising stock options and simultaneously selling 15,000 ordinary shares for a significant profit.

Summary

• Mario Alberto Accardi, President of the Orexin Program at Centessa Pharmaceuticals plc (CNTA), reported changes in his beneficial ownership.
• On June 24, 2025, Mr. Accardi acquired 15,000 Ordinary Shares by exercising stock options at a price of $3.85 per share.
• Concurrently, on June 24, 2025, he disposed of 15,000 Ordinary Shares at a sale price of $14.00 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Accardi on February 14, 2025.
• Following these transactions, Mr. Accardi beneficially owns 216,485 Ordinary Shares directly.
• He also holds 15,300 Share Options (right to buy) with an exercise price of $3.85, which began vesting on March 1, 2023, at a rate of 1/48th monthly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, the execution under a Rule 10b5-1 plan mitigates concerns about opportunistic trading. The significant profit realized by the insider also reflects positively on the stock's performance relative to the option exercise price.

Positives

• The reporting person, Mario Alberto Accardi, realized a substantial profit by selling shares at $14.00 that were acquired through options at $3.85, indicating a strong return on his vested equity.
• The transaction was executed under a Rule 10b5-1 trading plan, which suggests a pre-scheduled sale rather than a reaction to immediate company performance, potentially reducing negative market interpretation.

Negatives

• The sale of shares by an insider, even under a pre-arranged plan, could be perceived by some investors as a lack of confidence in the company's future stock price, although this is mitigated by the 10b5-1 plan.

Risks

• No specific risks are detailed in this Form 4 filing beyond the general market perception associated with insider selling, which is partially mitigated by the Rule 10b5-1 plan.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing is a routine insider transaction report for a biotechnology company. Such transactions are common for executives managing their equity compensation, especially when executed under a Rule 10b5-1 plan, which allows insiders to sell shares at pre-determined times to avoid accusations of trading on material non-public information.

Related Party Transactions

• The reported transactions involve an executive (Mario Alberto Accardi) of Centessa Pharmaceuticals plc, which are considered related party transactions in the context of insider trading regulations.

Stakeholder Impact

• Shareholders: May view the insider sale as a routine liquidity event under a pre-arranged plan, or potentially as an executive taking profits, which could be interpreted in various ways depending on individual investment strategies.
• Employees: No direct impact mentioned, but executive transactions can sometimes influence employee morale or perception of company value.

Next Steps

• The remaining 15,300 share options will continue to vest monthly, with the first installment having vested on March 1, 2023.

Key Dates

Keywords

Centessa Pharmaceuticals, CNTA, SEC Form 4, Insider Trading, Stock Options, Rule 10b5-1 Plan, Share Sale, Beneficial Ownership, Executive Compensation